Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP601 in solid tumors
NCT07165067Phase 1Recruiting
- Sponsor
- AP Biosciences
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of AP601 in solid tumor (6 cohorts), sponsored by AP Biosciences. Primary endpoints: Maximum Tolerated Dose at 28 days, Maximum Administered Dose at 28 days and 3 more. Started Jan 2026; status: recruiting.
02
Drugs
AP601
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07165067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165067.